The Pharmaceutical Institute of Education and Research of Uzbekistan received a patent for the drug against coronavirus.
Through the joint efforts of pharmacists and pharmacologists of this institute, based on natural and mineral sources, a multicomponent drug “Anticovir” was created by biotechnological and chemical synthesis.
Clinical and preclinical studies have shown that the drug prevents the penetration of coronavirus into cells with their subsequent damage and has an immunomodulatory effect aimed at increasing humoral immunity.
The components of the drug have anticoagulant, antioxidant, cytoprotective, immunomodulatory effects, as well as provide antibacterial and antiviral activity. Clinical studies showed high efficacy of the drug in 92% of patients, and no undesirable side effects were noted in the study group.
On November 13, 2020, the drug trademark was registered by the Intellectual Property Agency. On February 14, 2022, “Anticovir” was registered by the Ministry of Health as an antiviral drug recommended for the treatment and prevention of coronavirus infection and post-COVID syndrome.
The “Anticovir” drug received a patent No. IAP 06876 of the Ministry of Justice and was registered in the register of inventions of the Republic of Uzbekistan on April 7, 2022.
